Conditioning protocols and use of same for tissue regeneration

Abstract

A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.

Description

RELATED APPLICATIONS[0001]This application is a division of U.S. patent application Ser. No. 15 / 737,290 filed on Dec. 17, 2017, which is a National Phase of PCT Patent Application No. PCT / IL2016 / 050638 having International Filing Date of Jun. 16, 2016, which claims the benefit of priority under 35 USC §119(e) of U.S. Provisional Patent Application No. 62 / 181,394 filed on Jun. 18, 2015. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.FIELD AND BACKGROUND OF THE INVENTION[0002]The present invention, in some embodiments thereof, relates to conditioning protocols and to the use of same for tissue regeneration.[0003]Pancreatic diseases such as diabetes, pulmonary diseases such as COPD, cystic fibrosis, emphysema, pulmonary fibrosis or pulmonary hypertension, liver diseases such as liver cirrhosis or viral liver diseases (e.g. Hepatitis B or C), heart diseases such as heart failure, and kidney diseases such as kidney ...

AI Technical Summary

Benefits of technology

The present invention provides a method for conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest. The method involves inducing damage to the tissue of interest by administering an agent capable of inducing damage, followed by ablating the resident stem cells in the tissue. This results in the conditioning of the subject, which can then be followed by transplanting the progenitor cells to the subject. The method can be used for the treatment of various diseases, such as cystic fibrosis, emphysema, asbestosis, chronic obstructive pulmonary disease, pulmonary hypertension, lung cancer, sarcoidosis, and others. The progenitor cells can be obtained from various sources, such as cardiac, hepatic, pancreatic, brain, nephric, and others. The method can also involve the use of herbal remedies, chemicals, antibiotics, therapeutic drugs, toxins, surgical interventions, and other methods of inducing damage to the tissue of interest.

Problems solved by technology

Pancreatic diseases such as diabetes, pulmonary diseases such as COPD, cystic fibrosis, emphysema, pulmonary fibrosis or pulmonary hypertension, liver diseases such as liver cirrhosis or viral liver diseases (e.g. Hepatitis B or C), heart diseases such as heart failure, and kidney diseases such as kidney failure are diseases of great medical and economic impact for which no satisfactory / optimal treatments are available.

Most currently available therapies only slightly improve the quality of life for the patients in need.

At present, the only definitive treatment for end-stage lung disease, liver disease, heart disease and kidney disease is the replacement of the damaged organ, but many patients die while on the waiting list due to a severe shortage of organs for transplantation and the limit for inscription being often set at 60 years of age.

Such a treatment modality, however, suffers from considerable disadvantages.

Allogeneic transplantation of organs / tissues is impossible to implement in a great many cases due to the lack of organ donors (e.g. usually cadavers) and the unavailability of suitable immunologically matched organ donors.

Furthermore, the use of living human donors often presents health risks and ethical dilemmas.

Images